CHICAGO, April 29, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication ...

The Chicago-based startup formed in 2020 by Tempus AI executives Ryan Fukushima and Eric Lefkofsky is using an artificial intelligence platform, PathOS, to develop drugs, primarily in the oncology ...

CHICAGO, April 28, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop ...

The new, proprietary target discovery platform integrates RWD, human biological modeling, and CRISPR screens to accelerate novel target identification Tempus AI, Inc. (NASDAQ: TEM), a technology ...

The TIME Precision Network is a newly-formed group of investigators across TIME’s provider site network dedicated to supporting Phase I trials Tempus AI, Inc. (NASDAQ: TEM), a technology company ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this.

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas of disease. The companies said they will work together to train ...

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine with a market capitalization of $9.15 billion, announced the launch of Tempus Loop, a new platform designed to ...

The Tempus 2 is the second iteration of Saucony’s niche, support-meets-speed offering. True to its name, it’s a shoe that (on paper at least) is as much geared up for tempo sessions and ‘go ...

Tempus AI has a 52-week low of $22.89 and a 52-week high of $91.45. Insider Transactions at Tempus AI In related news, CEO Eric P. Lefkofsky sold 3,240,234 shares of Tempus AI stock in a ...